ReviewBrain & spine2026
Neurocognitive outcomes following glioma diagnosis and treatment: A systematic review.
Review in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gliomas are the most common primary malignant brain tumors in adults and are often accompanied by cognitive disturbances, which profoundly affect daily functioning and quality of life. Although survival and neurological deficits are routinely reported, neurocognitive outcomes remain insufficiently integrated into clinical decision-making. Research question: This review seeks to describe the patterns and progression of neurocognitive dysfunction in adult glioma patients and to clarify how tumor characteristics, patient-related factors, and treatment strategies influence cognitive outcomes. Additionally, we explore whether cognitive function may serve as a predictor of clinical outcome. Material and methods: A systematic literature review was performed following PRISMA guidelines. PubMed, Scopus, and Web of Science were searched from inception to August 2025. Studies involving adult glioma patients assessed with standardized neurocognitive instruments and reporting cognitive outcomes in relation to tumor features or treatment modalities were included. Study quality was evaluated using established risk-of-bias tools. Results: Twenty-five studies met our inclusion criteria. Cognitive impairment was frequently present at diagnosis, particularly in patients with tumors affecting eloquent brain regions. Surgical treatment was commonly associated with short-term cognitive decline, followed by stabilization or improvement in many patients over time. The effects of chemotherapy and radiotherapy on cognition were inconsistent. Tumor location, laterality, and histopathological grade emerged as key factors influencing cognitive trajectories. Preserved cognitive function was also associated with better quality of life and overall survival. Discussion and conclusion: Neurocognitive dysfunction in glioma patients is common, heterogeneous, and shaped by multiple interacting factors. Routine, standardized cognitive assessment and longitudinal follow-up are essential to better capture these changes and to incorporate cognitive outcomes into individualized glioma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.